208 related articles for article (PubMed ID: 38630656)
21. Clinical Pharmacology of RNA Interference-Based Therapeutics: A Summary Based on Food and Drug Administration-Approved Small Interfering RNAs.
Jing X; Arya V; Reynolds KS; Rogers H
Drug Metab Dispos; 2023 Feb; 51(2):193-198. PubMed ID: 36332914
[TBL] [Abstract][Full Text] [Related]
22. A review of nanocarriers for the delivery of small interfering RNA.
Kesharwani P; Gajbhiye V; Jain NK
Biomaterials; 2012 Oct; 33(29):7138-50. PubMed ID: 22796160
[TBL] [Abstract][Full Text] [Related]
23. RNAi therapeutic and its innovative biotechnological evolution.
Weng Y; Xiao H; Zhang J; Liang XJ; Huang Y
Biotechnol Adv; 2019; 37(5):801-825. PubMed ID: 31034960
[TBL] [Abstract][Full Text] [Related]
24. The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo.
Biscans A; Coles A; Echeverria D; Khvorova A
J Control Release; 2019 May; 302():116-125. PubMed ID: 30940496
[TBL] [Abstract][Full Text] [Related]
25. Nanotechnology for in vivo targeted siRNA delivery.
Dahlman JE; Kauffman KJ; Langer R; Anderson DG
Adv Genet; 2014; 88():37-69. PubMed ID: 25409603
[TBL] [Abstract][Full Text] [Related]
26. Nonviral in vivo delivery of therapeutic small interfering RNAs.
Aigner A
Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic siRNA: principles, challenges, and strategies.
Gavrilov K; Saltzman WM
Yale J Biol Med; 2012 Jun; 85(2):187-200. PubMed ID: 22737048
[TBL] [Abstract][Full Text] [Related]
28. Lipid Nanoparticle Systems for Enabling Gene Therapies.
Cullis PR; Hope MJ
Mol Ther; 2017 Jul; 25(7):1467-1475. PubMed ID: 28412170
[TBL] [Abstract][Full Text] [Related]
29. The road to therapeutic RNA interference (RNAi): Tackling the 800 pound siRNA delivery gorilla.
Meade BR; Dowdy SF
Discov Med; 2009 Dec; 8(43):253-6. PubMed ID: 20040280
[TBL] [Abstract][Full Text] [Related]
30. Clinical advances of siRNA therapeutics.
Hu B; Weng Y; Xia XH; Liang XJ; Huang Y
J Gene Med; 2019 Jul; 21(7):e3097. PubMed ID: 31069898
[TBL] [Abstract][Full Text] [Related]
31. siRNAs: their potential as therapeutic agents--Part II. Methods of delivery.
Singh SK; Hajeri PB
Drug Discov Today; 2009 Sep; 14(17-18):859-65. PubMed ID: 19540929
[TBL] [Abstract][Full Text] [Related]
32. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics.
Lorenzer C; Dirin M; Winkler AM; Baumann V; Winkler J
J Control Release; 2015 Apr; 203():1-15. PubMed ID: 25660205
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic face of RNAi: in vivo challenges.
Borna H; Imani S; Iman M; Azimzadeh Jamalkandi S
Expert Opin Biol Ther; 2015 Feb; 15(2):269-85. PubMed ID: 25399911
[TBL] [Abstract][Full Text] [Related]
34. Development of RNA interference-based therapeutics and application of multi-target small interfering RNAs.
Li T; Wu M; Zhu YY; Chen J; Chen L
Nucleic Acid Ther; 2014 Aug; 24(4):302-12. PubMed ID: 24796432
[TBL] [Abstract][Full Text] [Related]
35. Systemic siRNA delivery to leukocyte-implicated diseases.
Peer D; Shimaoka M
Cell Cycle; 2009 Mar; 8(6):853-9. PubMed ID: 19221492
[TBL] [Abstract][Full Text] [Related]
36. A non-covalent peptide-based strategy for siRNA delivery.
Crombez L; Charnet A; Morris MC; Aldrian-Herrada G; Heitz F; Divita G
Biochem Soc Trans; 2007 Feb; 35(Pt 1):44-6. PubMed ID: 17233597
[TBL] [Abstract][Full Text] [Related]
37. Strategies for in vivo delivery of siRNAs: recent progress.
Higuchi Y; Kawakami S; Hashida M
BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284
[TBL] [Abstract][Full Text] [Related]
38. Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy.
Mainini F; Eccles MR
Molecules; 2020 Jun; 25(11):. PubMed ID: 32532030
[TBL] [Abstract][Full Text] [Related]
39. siRNA therapeutics: a clinical reality.
Saw PE; Song EW
Sci China Life Sci; 2020 Apr; 63(4):485-500. PubMed ID: 31054052
[TBL] [Abstract][Full Text] [Related]
40. [Research progress on the development of the strategies for siRNAs delivery in vivo].
Tang D; Mao A
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Aug; 29(4):775-9. PubMed ID: 23016434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
